Just a moment, the page is loading...

GSK-110870




Immunogenicity & safety study of a booster dose of GSK Biologicals’ meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlers.
Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine
110870
NCT00614614 2012-002401-22
Infections, Meningococcal
Phase 3
Booster study 110871 was conducted. The results are summarised with this study 110870 on the GSK Study Register.
June 2015